Prostate-Specific Antigen (PSA)
| Clinical | Optimal | |
|---|---|---|
| Male | Age-dependent: 40-49yr: <2.5 µg/L; 50-59yr: <3.5 µg/L; 60-69yr: <4.5 µg/L; 70+yr: <6.5 µg/L | Age 40–49: <2.5 µg/L; Age 50–59: <3.5 µg/L; Age 60–69: <4.5 µg/L; Age 70+: <6.5 µg/L |
| Female | N/A | Not applicable |
What is Prostate-Specific Antigen (PSA)?
Prostate-Specific Antigen (PSA) is a protein enzyme produced by both normal and abnormal prostate cells. Its primary biological function is to liquefy semen, but small amounts enter the bloodstream, where they can be measured. PSA is not a cancer-specific marker — it is a prostate-specific marker, meaning any condition affecting the prostate can influence levels.
PSA testing is widely used as a screening tool for prostate health, including the detection of prostate cancer. However, it is important to understand that a raised PSA does not necessarily indicate cancer, and a normal PSA does not entirely exclude it. Context, trends over time, and additional clinical information are essential for accurate interpretation.
PSA naturally increases with age as the prostate gland gradually enlarges. This is why age-adjusted reference ranges are used for interpretation.
Why Prostate-Specific Antigen (PSA) Matters for Your Health
Prostate cancer is the most common cancer in men in the UK, with approximately 1 in 8 men being diagnosed during their lifetime. Early detection through PSA monitoring can lead to earlier intervention and significantly better outcomes. Regular PSA tracking allows for the identification of trends that may be more informative than any single result.
Beyond cancer screening, PSA provides insight into overall prostate health. Benign prostatic hyperplasia (BPH), prostatitis, and urinary tract infections can all raise PSA, and identifying these conditions early allows for proactive management.
For men interested in longevity and preventive health, baseline PSA testing from age 45 (or earlier if there is a family history of prostate cancer) provides a valuable reference point. The rate of PSA change over time (PSA velocity) is often more clinically meaningful than a single reading.
Prostate-Specific Antigen (PSA)& Your Wearable Data
Prostate-specific antigen (PSA) is a protein produced by the prostate gland, used as a screening marker for prostate cancer and to monitor prostate conditions. While wearable devices have no direct connection to PSA levels, general health monitoring through your wearable supports the overall health vigilance that includes appropriate cancer screening.
Exercise can transiently elevate PSA. Cycling in particular, through mechanical pressure on the prostate, can raise PSA levels for up to 48 hours. If your wearable shows cycling activity before your blood draw, this should be noted when interpreting results. Vigorous exercise of any type can also mildly elevate PSA, so testing on rest days identifiable from your wearable gives the most accurate baseline.
What High Prostate-Specific Antigen (PSA) May Suggest
Elevated PSA levels may suggest several conditions, including benign prostatic hyperplasia (BPH), prostatitis (inflammation or infection of the prostate), urinary tract infection, or prostate cancer. Recent ejaculation, vigorous cycling, or a digital rectal examination within 48 hours of the test can also temporarily raise PSA.
The higher the PSA level, the greater the statistical likelihood of prostate cancer, but there is significant overlap between benign and malignant causes. A PSA between 4 and 10 µg/L is sometimes called the 'grey zone,' where further investigation such as a free-to-total PSA ratio, MRI, or biopsy may be recommended.
If results suggest elevated PSA, your GP will typically recommend a repeat test before any further investigations, as transient elevations are common.
What Low Prostate-Specific Antigen (PSA) May Suggest
Low PSA levels are generally reassuring and suggest a lower risk of prostate disease. Very low PSA (below 1.0 µg/L) in men over 60 is associated with a very low long-term risk of clinically significant prostate cancer.
In some cases, very low PSA may be seen in men taking certain medications that shrink the prostate (such as 5-alpha reductase inhibitors), which can halve PSA levels. It is important to inform your GP if you are taking any such medications so that results can be interpreted accordingly.
There is no clinical concern associated with low PSA levels in general. A low baseline PSA in middle age is considered a positive indicator for prostate health.
How to Optimise Your Prostate-Specific Antigen (PSA)
Food
Support prostate health with lycopene-rich foods such as cooked tomatoes, watermelon, and pink grapefruit — lycopene has been associated with reduced prostate cancer risk in multiple studies. Include cruciferous vegetables (broccoli, cauliflower, kale) which contain sulforaphane, a compound with anti-cancer properties. Consume Brazil nuts for selenium, which supports prostate cell health. Oily fish rich in omega-3 fatty acids may help reduce prostate inflammation. Green tea contains catechins that have shown prostate-protective effects in research.
Lifestyle
Maintain a healthy body weight, as obesity is associated with more aggressive forms of prostate cancer. Engage in regular physical activity — at least 150 minutes per week of moderate exercise has been linked to improved prostate outcomes. Limit consumption of processed and red meat, which has been associated with increased prostate cancer risk. Avoid excessive cycling for prolonged periods if PSA is being monitored, as it can transiently raise levels. Abstain from ejaculation for 48 hours before a PSA test for the most accurate reading.
Supplements
Saw palmetto extract may support prostate health and has been traditionally used for benign prostatic symptoms. Zinc (15–30 mg daily) is concentrated in prostate tissue and supports normal prostate function. Vitamin D3 supplementation, particularly during UK winter months, may be beneficial as low vitamin D has been associated with increased prostate cancer risk.
When to Speak to Your GP
See your GP if PSA is above the age-adjusted reference range, if there is a significant rise between tests (PSA velocity greater than 0.75 µg/L per year), or if you experience urinary symptoms such as difficulty starting or stopping urination, increased frequency, or blood in the urine. Men with a family history of prostate cancer (father or brother) should begin PSA monitoring from age 45. Black men, who have a higher risk of prostate cancer, should discuss earlier screening with their GP.
References
- NHS. PSA testing — Overview. Updated 2024. nhs.uk
- NICE. Prostate cancer: diagnosis and management. NG131. nice.org.uk
- BMJ. Schroeder FH, et al. Screening and prostate-cancer mortality in a randomized European study (ERSPC). N Engl J Med. 2009;360(13):1320-1328. pubmed.ncbi.nlm.nih.gov
- Lancet. Martin RM, et al. Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality (CAP). JAMA. 2018;319(9):883-895. pubmed.ncbi.nlm.nih.gov
Medical Disclaimer— This content is for general educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Omniwo Ltd is a wellness information service and is not a medical device, clinical laboratory, or regulated healthcare provider under MHRA guidelines. The “optimal ranges” presented on this page are based on published clinical guidelines (WHO, NICE, NHS) and peer-reviewed research; they represent functional wellness targets and may differ from standard laboratory reference ranges. Individual results should always be interpreted by a qualified healthcare professional (such as your GP) who understands your full medical history. Do not start, stop, or change any medication or supplement based solely on this information. If you are experiencing symptoms, seek medical attention promptly.